Enliven Therapeutics, Inc. (ELVN) Research

Enliven Therapeutics, Inc. is a biopharmaceutical enterprise, currently in the clinical development phase, dedicated to discovering and advancing small molecule therapeutic agents aimed at combating cancer. Its pipeline includes ELVN-001, a small molecule kinase inhibitor currently in a Phase 1 clinical trial for adult patients with chronic myeloid leukemia. Another key candidate, ELVN-002, also a small molecule kinase inhibitor, has begun a Phase 1 clinical assessment for individuals with cancers exhibiting an abnormal HER2 gene. The company's base of operations is located in Boulder, Colorado.

Market snapshot

Symbol
ELVN
Price
$45.10
Day change
+0.54%
Market cap
$2.7B
P/E ratio
-28.67x
52-week range
14.785-48.53
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 2 months
Analyst price target
$65.25

Peer companies

  • Atai Beckley Inc. (ATAI)
  • Dianthus Therapeutics, Inc. (DNTH)
  • Immatics N.V. (IMTX)
  • Inhibrx Biosciences, Inc. (INBX)
  • Nektar Therapeutics (NKTR)
  • ORIC Pharmaceuticals, Inc. (ORIC)
  • Precigen, Inc. (PGEN)
  • Relay Therapeutics, Inc. (RLAY)

Recent insider activity

  • ORBIMED ADVISORS LLC — S-Sale (272322 shares) on 2026-06-15
  • ORBIMED ADVISORS LLC — S-Sale (9086 shares) on 2026-06-15
  • Kunkel Lori Anne — S-Sale (7779 shares) on 2026-06-05
  • Kunkel Lori Anne — S-Sale (1867 shares) on 2026-06-05
  • Kunkel Lori Anne — S-Sale (354 shares) on 2026-06-05

Open Enliven Therapeutics, Inc. (ELVN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.